All News
Factors associated with non-achievement of MDA in PsA pts receiving golimumab:
Baseline tender joint count, fibromyalgia, older age, smoking, high BMI
Abs#2109 @RheumNow #ACR22 https://t.co/dEzQxVtavh
Robert B Chao, MD doctorRBC ( View Tweet)
‼️‼️Frailty ‼️‼️
👉Important predictor of serious infxn in RA pts on b- or tsDMARD irrespective of age ‼️‼️
@NamrataRheum illustrating yet another reason why it is so NB to evaluate 4 frailty in ALL (incl young) pts with RA
#GeriRheum
Abst2218 @RheumNow #ACR22 https://t.co/J4XQFmVoUw
Patricia Harkins DrTrishHarkins ( View Tweet)
While there are limitations to this study (respondents over childbearing age, white, educated, insured), within 2 months of @USSupremeCourt3's overturn of Roe v Wade, 1 in 17 MTX pts experienced a barrier to getting rx filled. ABS L09 @RheumNow #ACR22 https://t.co/WuikwO1bZ9 https://t.co/4Ve0zAVxbG
Dr. Rachel Tate uptoTate ( View Tweet)
Early psoriasis and enthesitis response in PsA pts treated with guselkumab predicted longterm clinical response including MDA, DAPSA LDA, DAPSA50, DAPSA remission.
Pts w/o early response, only half achieved remission
Abs#2115 @RheumNow #ACR22 https://t.co/dnsQcp7cEq
Robert B Chao, MD doctorRBC ( View Tweet)
BKZ showed clinically meaningful improvements in efficacy outcomes in bDMARD-naïve PsA pts at Wk 16 through wk 52. No new safety signals. ABS L02 #ACR22 @RheumNow https://t.co/Dph32O7NWG https://t.co/d7Yq3JISyF
Dr. Rachel Tate uptoTate ( View Tweet)
I think this has changed my mind!
Does RA benefit from changes in diet & exercise?
RCT Reade @amsterdamumc n=77
mod active RA
https://t.co/5Iw6hYJzGK for 16w:
whole food plant-based diet/exercise/stress management
0.9 improvement in DAS28 vs placebo!
ABST1998 #ACR22 @RheumNow https://t.co/u10RqmPMPd
Links:
David Liew drdavidliew ( View Tweet)
PsA bDMARD "ranking" system by systematic literature review looked at 30 RCTs
Highest probability of achieving ACR20 and PASI90: infliximab, golimumab and bimekizumab
#ACRBest Abs#2123 @RheumNow #ACR22 https://t.co/KpW0p2KAQZ
Robert B Chao, MD doctorRBC ( View Tweet)
🔥PrEP 4 SARS-CoV-2🔥
➡️casirivimab/imdevimab
⚡️Detection @ D1 and stabilisation up to D30 of serum and saliva Abs in IMID pts who failed response 2 COVID vax.
❓role in preventing severe infxn in high risk pts refractory 2 vax
#ACR22 @RheumNow Abst 2195 @Dr_David_Simon https://t.co/Zd00P5l363
Patricia Harkins DrTrishHarkins ( View Tweet)
Abstr # 1878 looked at biomarkers assoc w/ MRI muscle inflammation in #IIM
- Of the potential cytokines, IL-7 strongly correlated with muscle damage on MRI thigh bilateral
@RheumNow #ACR22 #Myositis https://t.co/3i3C2EGtFM
Akhil Sood MD AkhilSoodMD ( View Tweet)
Smartphone app (FM-ACT) - self guided 8 chapters of structured lessons, mindfulness practices and activities w/ paced exercise and behavior change proved beneficial after 12 weeks.
Improvement in all areas: pain, sleep, psychological wellbeing
Abs#2235 @RheumNow #ACR22 https://t.co/wNhIw4pdJu
Robert B Chao, MD doctorRBC ( View Tweet)
61pts with #FMF on Canakinumab - single center in Turkey
35% no attacks
attack frequency decreased in 55%
no response in 10%
- VAS score and inflammatory markers significantly improved
#ACR22 @RheumNow abst#1834
Bella Mehta bella_mehta ( View Tweet)
#abst0405 #ACR22 @RheumNow Post hoc of ph2/3 trials TOFA for AS: AEs/SAEs ⬆️ in pts w/BMI < 25 kg/m2 vs other BMI categories. Most frequent AEs (≥ 5% of pts) nasopharyngitis, URI& arthralgia. Δ from BL in LFTs similar, while % change from BL in lipid levels ⬆️ in Tofa vs PBO pts https://t.co/WmXD8uVK58
Olga Petryna DrPetryna ( View Tweet)
Males w/ sarcoidosis may be more likely to have cardiac involvement. Patients treated with s/bDMARDs had a high response rate as reflected by clinical and imaging improvement. Abs 1846 @RheumNow #ACR22 https://t.co/ibbf4Dckun https://t.co/ZvGxPNFjwm
Dr. Rachel Tate uptoTate ( View Tweet)
In bio-naïve PsA pts on GUS, earlier improvements in self-reported health-related measures were sustained through 2 years. Abs 1850 #ACR22 @RheumNow https://t.co/6yhPesE3LZ https://t.co/nVCSgPgcqW
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR22 Abstr#L07 Most impressive Delta difference vs Control in #lupus! In Phase 3 RCT in China, more patients in Telitacicept, BAFF/APRIL-i met SRI-4 (delta 44% if data imputed; 34% without). No major safety. Phase 3 in US is in progress. Would be historic! @RheumNow #ACRBest https://t.co/8wL2tkA8ym
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Jonassen et al. AP1189, an oral melanocortin agonist in combination with MTX in early RA. Evidence of efficacy, no safety concerns. Looks promising! @RheumNow #ACR22 Abstr#1985 https://t.co/aK7BPwr5Ku https://t.co/9553KT2Pao
Richard Conway RichardPAConway ( View Tweet)
van Ouwerkerk et al. Glucocorticoid bridging in new RA associated higher risk of starting bDMARD (aHR 1.68) but not glucocorticoids (aHR 1) later in disease. Why? Maybe it shows what can be achieved? @RheumNow #ACR22 Abstr#1994 https://t.co/5GsXGMOZAm https://t.co/122CuSAqVw
Richard Conway RichardPAConway ( View Tweet)
Damart et al. Treatment strategies in CPP arthritis. Colchicine(1st line=73/86), MTX (second line=22/36), anakinra (n=27) and TCZ (n=25) most used. Drug survival MTX vs colchicine HR 0.64, TCZ vs anakinra HR 0.55 @RheumNow #ACR22 Abstr#1795 https://t.co/4PtxQNmTqV https://t.co/BKM4Ff9Gkk
Richard Conway RichardPAConway ( View Tweet)
#ACR22 Abs 1863 Aromatase Inhibitor induced musculoskeletal inflammation observed independent of oophorectomy in novel mouse model, may not be E2 related as previously thought. @RheumNow https://t.co/XhUaGQX88p
Dr. Rachel Tate uptoTate ( View Tweet)
Are we asking women with IPAF about family planning?
Abstract #0944 #ACR22 @RheumNow
🫁 31 women
🤰83% had RF for adverse pregnancy outcomes
👼1/3 women had family plan. or birth control talks with pulm. docs
✋>50% women who saw a rheumatologist discussed these topics
Catherine Sims, MD DrCassySims ( View Tweet)